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Abstract
Background: In lung cancer screening, a nodule management protocol describes nodule assessment and
thresholds for nodule size and growth rate to identify patients who require immediate diagnostic evaluation or
additional imaging exams. The Netherlands-Leuvens Screening Trial and the National Lung Screening Trial used
different selection criteria and nodule management protocols. Several modelling studies have reported variations in
screening outcomes and cost-effectiveness across selection criteria and screening intervals; however, the effect of
variations in the nodule management protocol remains uncertain. This study evaluated the effects of the eligibility
criteria and nodule management protocols on the benefits, harms and cost-effectiveness of lung screening
scenarios in a population-based setting in Germany.
Methods: We developed a modular microsimulation model: a biological module simulated individual histories of
lung cancer development from carcinogenesis onset to death; a screening module simulated patient selection,
screening-detection, nodule management protocols, diagnostic evaluation and screening outcomes. Benefits
included mortality reduction, life years gained and averted lung cancer deaths. Harms were costs, false positives
and overdiagnosis. The comparator was no screening. The evaluated 76 screening scenarios included variations in
selection criteria and thresholds for nodule size and growth rate.
Results: Five years of annual screening resulted in a 9.7–12.8% lung cancer mortality reduction in the screened
population. The efficient scenarios included volumetric assessment of nodule size, a threshold for a volume of
300 mm3 and a threshold for a volume doubling time of 400 days. Assessment of volume doubling time is essential
for reducing overdiagnosis and false positives. Incremental cost-effectiveness ratios of the efficient scenarios were
16,754–23,847 euro per life year gained and 155,287–285,630 euro per averted lung cancer death.
Conclusions: Lung cancer screening can be cost-effective in Germany. Along with the eligibility criteria, the nodule
management protocol influences screening performance and cost-effectiveness. Definition of the thresholds for
nodule size and nodule growth in the nodule management protocol should be considered in detail when defining
optimal screening strategies.
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Background
The National Lung Screening Trial (NLST) in the USA
[1] has shown that lung screening with low-dose com-
puted tomography (LDCT) can reduce lung cancer mor-
tality by 20%, but it also can induce harms that the
screened population may experience, i.e. false-positive
findings, overdiagnosed cases, radiation-related deaths
and interval cancers [2–5]. The largest lung screening
trial in Europe, the Netherlands-Leuvens Screening Trial
(NELSON) [6], used less stringent selection criteria and
a different approach to patient management and has re-
ported a reduced number of false positives compared to
NLST [7]. The nodule management protocols of NLST
and NELSON differ in applied measurement techniques
(diametric vs volumetric assessment), follow-up algo-
rithms and the definition of a cut-off nodule size indicat-
ing a cancer-positive result [8]. However, other differences
between the studies (e.g. screened cohort, screening inter-
vals) make it difficult to recognise the potential of nodule
management approaches to succeed in the reduction of
harms of screening.
Designing a screening program with an optimal balance
between the benefits, harms and/or cost-effectiveness has
become a major challenge for healthcare decision-makers
who manage development of a lung screening program
and decide on population selection strategies and screen-
ing intervals [7, 9, 10] as well as for clinicians who decide
how to manage a screening-detected lung nodule [7].
Several modelling studies have examined trade-offs be-
tween the benefits and harms of LDCT screening and
contributed to comprehension of the effects that eligibil-
ity criteria and screening intervals might have on its
long-term screening performance and cost-effectiveness
[11–18]. However, the effects of nodule management
strategies have not been investigated in detail, and our
understanding of how to proceed with a screening-de-
tected nodule remains limited [19]. An algorithm for
nodule assessment and management determines ways
to prognosticate malignancy, defines core procedures of
a screening program and may strongly influence the
screening outcomes [20].
In this modelling study, we aimed to investigate the ef-
fects of the eligibility criteria and nodule management
on the benefits, harms and cost-effectiveness of lung
screening with LDCT in a population-based setting.
Methods
Microsimulation model
We developed a stochastic modular microsimulation
model that simulated individual life histories focusing on
the development of lung cancer and its progression from
the onset of the first malignant cell to death from lung
cancer.
The model consists of the following structural modules:
population, natural history, clinical detection, survival,
screening and life history (Fig. 1). The model was popu-
lated with 10% of the German population aged 40 years
and older. Data on smoking behaviour was obtained
from the German Health Update (GEDA) survey (years
2009–2012) [21], and the demographic structure of 2012
was obtained from the German statistical office [22].
The natural history module contains a biological two-
stage clonal expansion (TSCE) model [23] and a tumour
growth component and simulates a complete flow of
events in the development of lung cancer (details are
available in Additional file 1: Section 1.1.2). The TSCE
model defines the individual age at the onset of the first
malignant cell and the histologic cancer type: small cell,
large cell, squamous cell carcinoma, adenocarcinoma or
adenocarcinoma in situ (AIS). The progression of lung
cancer is described via tumour growth, lymph nodes in-
volvement and metastasis. The tumour growth is defined
by a Gompertz function [24] (Additional file 1: Section
1.1.4.2). This function describes the relation between
time and the tumour volume. For a specific tumour vol-
ume the function gives the time needed to reach this
volume and vice versa. The module uses the age at the
onset of the first malignant cell and the time to reach
the stage-specific volume and gives the age at different
stages of the progression of the disease. Threshold
tumour volumes at the stages of nodal involvement, dis-
tant metastases and clinical diagnosis are randomly
drawn from log-normal distributions (Additional file 1:
Table S5), and the tumour growth model is applied to
calculate the corresponding ages of the individual. The
clinical detection module determines the stage of lung
cancer (I, II, III, IV) according to the tumour-node-
metastasis (TNM) staging system based on the tumour
volume and spread (local, nodal involvement, distant
metastasis) at the age of diagnosis (Additional file 1:
Section 1.1.3).
The lung cancer survival is modelled as long-term sur-
vival, which lets the individual live until death from
other causes, and short-term survival in years, which fol-
lows the Weibull distribution [25]. The parameters vary
over the histological classes and stages at the time of
diagnosis (Additional file 1: Table S1, Section 1.1.3) [25].
The screening module (Additional file 1: Section 1.1.5)
contains several structural components: eligibility assess-
ment, screening-detection, nodule management (including
follow-up), diagnostic work-up and lung cancer survival.
For each individual it creates a screening schedule based
on eligibility criteria and nodule management protocol. At
each screening exam, the module checks for presence of a
lung nodule and determines its volume using the tumour
growth function, the individual’s age and the age at the on-
set of the first malignant cell. Screening-detection depends
Treskova et al. BMC Medicine  (2017) 15:162 Page 2 of 15
on the location and volume of the tumour and the sensi-
tivity of the CT scan (Additional file 1: Section 1.1.5.2,
Table S7). Individuals with a detected nodule proceed with
a nodule management algorithm. The nodule manage-
ment algorithm defines the threshold values of the nodule
size and tumour growth and indicates the patients who re-
quire immediate diagnostic work-up or undergo additional
imaging exams (follow-up course).
Two nodule management algorithms were designed
based on those used in the NELSON and NLST trials.
Schematic representations of the algorithms are given in
Figs. 2 and 3. The modelled NELSON-like nodule man-
agement algorithm includes volumetric assessment of
the nodule size. Based on the nodule volume, the patients
undergo either the next screening round (if negative), a
follow-up exam 3 months later (if indeterminate) or an
immediate diagnostic evaluation (if positive) [6, 26]. At the
follow-up examination, tumour growth and tumour vol-
ume doubling time (VDT [6]) are assessed as an additional
malignancy predictor.
The NLST-like nodule management algorithm includes
diametric assessment of the nodule size and defines three
categories of screening results: negative, positive intermedi-
ate and positive (Fig. 3). In contrast to the NELSON-like
nodule management algorithm, individuals with positive
intermediate initial results undergo a course of follow-up
chest imaging exams where tumour growth is assessed as a
change (%) in the nodule diameter relative to the result at
the initial screening. The follow-up can occur with a fixed
periodicity: at 3, 6 and 12 months after the initial screening.
Additional details on the modelled nodule management
protocols are available in Additional file 1: Section 1.1.5.3.
Individuals with lung cancer, defined in the management
algorithm, undergo the diagnostic work-up component
(Additional file 1: Section 1.1.5.4), and the tumour is staged
according to TNM classification based on the volume and
spread. These patients are withdrawn from the regular
screening schedule.
We assume that individuals with screen-detected lung
cancer live at least as long as they would in the no
screening scenario. In the screening module lung cancer,
survival component alters the age of death from lung
cancer for the persons with a screen-detected lung can-
cer at stages I and II: if they die from lung cancer in the
no screening scenario, they receive 40% probability of
long-term survival [25]. The screening module sums up
imaging exams, work-ups, complications and treatments.
The life history module computes false positives and
interval cancers and calculates overdiagnosed cases and
deaths from radiation-induced cancer (Additional file 1:
Section 1.1.6). Figure 4 gives a schematic representation
of the modelling of the tumour growth and interaction
between the natural history, screening, clinical diagnosis
and survival modules.
Fig. 1 Structural modules of the microsimulation model. * refers to the case in which the patients would die from lung cancer in the no
screening scenario
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Fig. 3 Schematic representation of modelled NLST-like nodule management protocol. *Growth is calculated as a percentage increase in the diameter
vs the diameter at the initial screening. Dcut and Growthcut indicate the threshold values of the diameter and percentage increase in the diameter that
indicate a cancer positive result. Dfup represents low threshold diameter for a follow-up examination
Fig. 2 Schematic representation of modelled NELSON-like nodule management protocol. Vcut and VDTcut indicate the threshold values of the
volume and volume doubling time which indicate a cancer positive result. Vfup represents low threshold volume for a follow-up examination
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Screening scenarios
At base case, a 5-year LDCT annual lung screening
program with perfect adherence was evaluated. Over-
all, 76 scenarios were constructed using variations of
the eligibility criteria (four different screened popula-
tions) and nodule management protocol (defined as
the NELSON-like or NLST-like protocol) (Table 1).
The outcomes were projected over the course of a life-
time. Lung cancer-specific mortality reduction and
false-positive cases were calculated for the screened
cohort.
Health economics
Costs included LDCT exams, staging tests and lifetime
treatment (Additional file 1: Table S8). Expenditures of
lifetime treatment, due to limitations of available cost
data for Germany, were calculated via application of cost
variations across cancer stages obtained from the UK
cost data [27] compared with the German cost data [28]
(Additional file 1: Section 1.3). The lifetime treatment
costs for patients with early-stage and advanced cancers
were 45,803 euro for stages I/II and 30,101 euro for
stages III/IV.
Fig. 4 Schematic representation of modelled tumour growth and interaction between the natural history, screening, clinical diagnosis and
survival modules. NMP nodule management protocol. The curve schematically represents the tumour growth. Figure does not reflect the scales.
The natural history module contains a biological two-stage clonal expansion (TSCE) model and a tumour growth component and simulates for
each individual the age at the onset of carcinogenesis, its histological features, the age and tumour size at the lymph nodes involvement and
distant metastasis. The TSCE model simulates age at the cancer onset for each histological class. The final histological class for the individual
is determined based on the competing risk (the lowest age at onset). The tumour growth component applies a Gompertz function which
describes the relation between time (age) and the tumour volume. The clinical diagnosis model determines the age at lung cancer diagnosis
and stage of the tumour according to TNM classification using the tumour growth model and information on the tumour progression from
the natural history module. The screening module simulates an individual screening schedule based on the eligibility criteria. It applies the
tumour growth module to determine the tumour volume at age of screening and uses information on the tumour progression for staging
the screen-detected tumour according to TNM classification. The survival model determines the age of death based on the tumour stage and
histological class. The figure illustrates a case where an individual in the no screening scenario develops a lung cancer tumour and is eventually
symptomatically diagnosed with lung cancer at stage IV. The patient dies from lung cancer in the no screening scenario. In the screening scenario, a
nodule (tumour) is detected in the first round of screening. The screen-detected nodule is small for the patient to undergo an immediate diagnostic
evaluation. The patient undergoes a follow-up exam, where the growth is assessed according to the NMP. The growth and/or the volume doubling
time meet the definition of cancer according to the NMP. The screen-detected tumour is at the local stage, and the patient is diagnosed with
lung cancer at stage I in the screening scenario. The patient is cured and dies from other causes. The model calculates life years gained for
each individual in the screened cohort
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Cost-effectiveness was represented by average and in-
cremental cost-effectiveness ratios (ACER and ICER,
respectively). Life years gained (LYG) and averted lung
cancer deaths constituted the main benefits of the
screening. We applied equal (3%) and differential (3% for
costs and 1.5% for LYG) annual discounting. A health in-
surance perspective was used.
Sensitivity analyses
One-way sensitivity analyses were performed to assess
variations of the cost-effectiveness after altering assump-
tions about LDCT sensitivity parameters, parameters of
long-term survival after screening, attendance rate cost
per CT exam and lifetime treatment costs (Additional
file 1: Section 1.4).
Results
Benefits and harms of screening
Annual screening led to a 9.7–12.8% reduction in lung
cancer mortality in the screened cohorts. Relative to
usual care, where 79% of cancers were diagnosed at
stages III and IV, a screening program shifted the majority
of diagnoses towards the early-staged cancers (stages I/II
accounted for 66.4–71.7%). Adenocarcinomas (around
Table 1 Characteristics of the evaluated screening scenarios
Characteristics Considered variations
Eligibility criteria
Population: 50-74-30-15
Values arranged as (eligibility criteria of the NLST clinical trial)
age at begin smoking - age at quit smoking - minimum pack years - maximum
years since quitting smoking
55-80-30-15
(as recommended by the US Preventive Services Task Force
(USPSTF) for lung screening with LDCT [2])
50-75-15-9
(less restrictive eligibility criteria, similar to the NELSON trial)
55-75-40-10
(more restrictive eligibility criteria) [18]
Nodule management algorithm
NELSON-like VDTcut = 400 days – Vcut = 500 mm
3
Scenario is characterised by the threshold value of the volume doubling time
(VDTcut) and the cut-off volume (Vcut) for cancer positive
(values of the NELSON clinical trial)
VDTcut = 400 days – VDTcut = 300 mm
3
VDTcut = 400 days – VDTcut = 400 mm
3
VDTcut = 400 days – VDTcut = 750 mm
3
VDTcut = 300 days – VDTcut = 500 mm
3
VDTcut = 600 days – VDTcut = 500 mm
3
VDTcut = 300 days – omitting VDTcut
a
VDTcut = 400 days – omitting VDTcut
a
VDTcut = 600 days – omitting VDTcut
a
Vfup = 80 mm
3 – VDTcut = 400 days – VDTcut = 500 mm
3b
NLST-like Growthcut = 10% – Dcut = 10 mm
Scenario is characterised by the threshold value of the tumour growth and the
diameter (Dcut) for cancer positive
(values of the NLST clinical trial)
Growthcut = 10% – Dcut = 9 mm
Growthcut = 10% – Dcut = 11 mm
Growthcut = 7.5% – Dcut = 10 mm
Tumour growth (threshold growth, Growthcut) is defined as a percentage increase
in diameter
Growthcut = 12.5% – Dcut = 10 mm
Growthcut = 7.5% – omitting Dcut
a
Growthcut = 10% – omitting Dcut
a
Growthcut = 12.5% – omitting Dcut
a
Dfup = 5 mm – Growth = 10% – Dcut = 10 mm
b
aIn these scenarios nodule growth is taken as a single malignancy predictor
bIn these scenarios a higher nodule size for the follow-up exams (Vfup; Dfup) is used according to the British Thoracic Society guidelines [29]. In other scenarios the
value of nodule size for follow-up exams is applied according to the trials as 4 mm (NLST-like) and 50 mm3 (NELSON-like)
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50%), squamous cell carcinomas (around 23.4%) and AIS
(around 18.2%) constituted the majority of screening-
detected cancers. Around 77.2% of screening-diagnosed
AIS were overdiagnosed cases. Overdiagnoses constituted
9–21.5% of all screening-detected lung cancers. Small cell
carcinomas were rarely detected at screening (around
5.35%) but constituted 56% of all interval cancers. False-
positive diagnoses constituted 59.4–96% of all screening
findings.
Eligibility criteria have a considerable influence on the
main outcomes of a large-scale screening program. Eval-
uated scenarios with a selection of people similar to the
eligibility criteria of the NLST clinical trial (55-74-30-15)
gained 192,147–240,626 life years (ranged over the varia-
tions of the nodule management protocol) and 20,335–
25,467 averted deaths due to lung cancer and induced
3780–5069 million euro costs additional to no screening.
The scenarios with the increased threshold of exposure
to smoking (40 pack-years and maximum 10 years since
quitting) limited the screened population and yielded
around 31% less LYG (133,222–164,864) and 29% less
averted deaths (14,373–17,889) and induced 37% fewer
costs (2231–3178 million euro). Increasing the stopping
age to 80 (55-80-30-15) yielded around 8.3% additional
LYGs (207,468–260,807) and 14.4% more averted lung
cancer deaths (23,029–29,165) compared to the 55-74-
30-15 scenarios and a slightly increased reduction in
lung cancer mortality (12.4%); however, it induced around
13.5% more costs (4159–5811 million euro) and the
highest rate of overdiagnosis. Scenarios with the least
restrictive eligibility criteria, 50-75-15-9, resulted in
50.5% more LYGs (295,093–362,039) and 45.6% more
averted lung cancer deaths (30,147–37,075) vs the 55-
74-30-15 scenarios; however, they led to 57% more
healthcare costs (6447–8026 million euro additional to
no screening) and a higher number of CT scans.
Generally, the scenarios with the NELSON-like nodule
management protocol resulted in 1.1–1.3% fewer lung
cancer findings, but around 2.3% more findings of can-
cer at an early stage, 3.3–3.4% more cases of averted lung
cancer deaths, around 3% more LYGs, 0.1–0.9% fewer
overdiagnosed cases and around 3% more interval cancers
than the NLST-like strategies. The NLST-like scenarios
yielded around 51–57.4% more follow-ups of malignant
nodules and considerable additional costs.
Overall, across the evaluated 76 scenarios, a few tenden-
cies in the effects of the nodule management protocols
could be seen: (1) increasing the threshold for nodule size
for a cancer-positive diagnosis slightly decreased overdiag-
nosis, LYG and averted lung cancer deaths; (2) decreasing
the cut-off size yielded more overdiagnosed cases but did
not improve numbers of LYG and averted lung cancer
deaths; (3) altering threshold values for a cancer indicating
nodule growth when the cut-off volume stayed the same
did not appreciably change the rates of LYG and averted
lung cancer deaths; (4) application of VDT or an increase
in diameter as a single malignancy predictor in the two-
step framework remarkably reduced the accuracy of lung
cancer diagnosis, but it also notably decreased rates of
overdiagnosis. Increasing the threshold nodule size for a
follow-up in the NELSON-like scenarios from a volume of
50 mm3 to 80 mm3 and in the NLST-like scenarios from a
diameter of 4 mm to 5 mm, as recommended by the
British Thoracic Society [29], led to a 5% and 4% de-
crease in overdiagnosis and a 3.7–5% decline in LYG
and averted lung cancer deaths.
Cost-effectiveness of screening
ACER ranged from 16,754 to 24,160 euro/LYG (Fig. 5)
and from 155,287 to 230,678 euro/averted lung cancer
death (Fig. 6). Out of the 76 evaluated scenarios, three
scenarios were judged to be efficient based on their cost/
LYG ratio and five scenarios based on their cost per
averted lung cancer death ratio (Table 2).
The scenarios that featured NELSON and NLST
clinical trials were less efficient (Figs. 4 and 5, NLST-
and NELSON-resembling scenarios). Compared to the
NELSON-like scenarios, NLST-based screening over
5 years of annual screening would result in considerably
more total costs (around 450 million euro) while yielding
around 800 fewer averted deaths. Considering the cost per
life year gained ratio, characteristics of the not-dominated
scenario included the most restrictive eligibility criteria
(55-74-40-10) and the NELSON-like nodule management
protocol which applies the assessment of VDT 3 months
after the initial screening as a sole malignancy predictor
(Scenario 65, Table 2). The scenario yielded an ICER of
16,754 euro/LYG. The second efficient scenario (Scenario
60, Table 2) combined the threshold VDT of 400 days and
a cut-off nodule volume of 300 mm3. This scenario gained
31,642 additional life years for an incremental cost of
19,707 euro/LYG. The third efficient scenario (Scenario
41, Table 2) applied the same nodule management proto-
col and less stringent eligibility criteria (50-75-15-9). It
gained an additional 197,174 life years for an incremental
cost of 23,837 euro/LYG.
Two of the five scenarios, which were judged to be
efficient based on averted cancer deaths, included the
most restrictive selection criteria (55-75-40-10) and as-
sessment of VDT 3 months later than the initial screen-
ing as a sole malignancy predictor for individuals with
initial findings over 50 mm3 in volume (Scenarios 64
and 65, Table 2). The scenario with the lowest ICER of
155,287 euro per averted death (Scenario 65 with
threshold VTD of 300 days) yielded 14,373 averted
deaths. Increasing the threshold value of VDT to 400 days
gained an additional 1000 averted deaths for an incremen-
tal cost of 161,124 euro (Scenario 64). The inclusion of the
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cut-off volume of 300 mm3 (Scenario 60) into the nodule
management algorithm yielded 2500 more averted deaths
for an incremental cost of 184,009 euro. The scenario with
less restrictive selection criteria of exposure to smoking
and the increased stopping age (55-80-30-15, Scenario 22)
yielded 11,276 more averted lung cancer deaths for an
ICER of 216,454 vs the previous efficient scenario. The
scenario with the largest number of LYG (Scenario 41) is
also the scenario with the largest yield of averted cancer
deaths (37,075) for an ICER of 285,630 euro per averted
death.
Sensitivity analyses
Figure 7 illustrates the discounted life years and additional
costs (vs no screening) for the three efficient scenarios
(Scenarios 65, 60 and 41) and for their variations in the
sensitivity analyses. The main cost-effectiveness drivers
are cost per CT exam, treatment costs and lung cancer
long-term survival probability in screening. Relative to the
baseline long-term survival probability (40%), its reduction
to 20% led to a more than 50% reduction in LYG and
averted deaths with a more than 100% increase in cost/
LYG. Increase in cost per CT exam would have a stronger
adverse effect on the cost-effectiveness if the less restrict-
ive eligibility criteria were used. More expensive treatment
with innovative targeted medication at a lifetime cost of
77,702 euro [28] would increase the ACER by 65%. An in-
crease of the CT sensitivity for smaller nodules would
slightly improve the cost-effectiveness; a 20% decrease of
the sensitivity would lead to a more than 10% increase in
Fig. 5 The cost-effectiveness (cost per life year gained) of all evaluated scenarios and the scenarios that constitute an efficient frontier. The figure
illustrates three scenarios judged to be efficient based on the cost per life year gained ratio. These scenarios constitute the efficient frontier. The
other 73 evaluated scenarios are illustrated according to the population selection criteria and applied nodule management protocol (NMP). The
figure illustrates the four evaluated eligibility criteria in different colours: 55-75-40-10 is given in green, 55-74-30-15 is given in violet, 55-80-30-15 is
given in orange and 50-75-15-9 is given in dark blue. The scenarios which apply the NLST-like nodule management are illustrated with a circular
shape. The scenarios which apply the NELSON-like nodule management are illustrated with a triangular shape. The figure does not specify in
colour or a shape the evaluated variations of the threshold values for the tumour size and growth in the NELSON-like and NLST-like scenarios.
The scenarios which resemble the eligibility criteria and nodule management protocols of the NLST and NELSON clinical trials are illustrated in
light blue. Descriptions of the scenarios are given in Table 1. Main outcomes and cost-effectiveness of the 76 baseline screening scenarios are
given in Additional file 1: Table S12
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ACER. Compared with perfect adherence (100%), decreas-
ing adherence to 85% for the years following the initial
screening led to a modest decline of ACER (around 1%).
Screening strategy 60 (55-75-40-10-NELSON-VDT400-
V300) becomes inefficient in the scenarios of the de-
creased adherence, decreased cost per CT exam and
increased treatment cost (i.e. innovative treatment
scenario). Due to high rates of detection and overdiag-
nosis, factors that increase ratio of treatment relative
to the costs of screening have adverse effects on ICER
compared to the previous efficient scenario. Scenario
65 (55-75-40-10-NELSON-VDT300-only) in turn becomes
inefficient under conditions of increased screening costs.
Expanding the period of the screening to 10 years did
not considerably influence the cost-effectiveness. Detailed
results of baseline and sensitivity analyses are available in
Additional file 1: Sections 2.2–2.4.
Discussion
The microsimulation analysis shows that lung cancer
screening of the high-risk population in Germany can be
cost-effective. A program with less restrictive eligibility
criteria would be more effective but would induce a
higher ICER due to screening of people with a lower risk
of lung cancer development. The selection of heavier
smokers and limitation of the screened population yields
the lowest cost-effectiveness ratio compared with the no
screening scenario. Increasing the stopping age, i.e. follow-
ing the recommendations of the USPSTF [2], prevents
additional deaths from lung cancer but also leads to con-
siderable additional costs and increased overdiagnosis.
Overall, if decision-making is based on the results of esti-
mation of efficiency of an intervention, the scenarios that
constitute an efficient frontier should be considered for
implementation because other scenarios are proven to be
Fig. 6 The cost-effectiveness (cost per averted lung cancer death) of all evaluated scenarios and the scenarios that constitute an efficient frontier.
The figure illustrates five scenarios judged to be efficient based on the cost per averted lung cancer death ratio. These scenarios constitute the
efficient frontier. The other 71 evaluated scenarios are illustrated according to the population selection criteria and applied nodule management
protocol (NMP). The figure illustrates the four evaluated eligibility criteria in different colours: 55-75-40-10 is given in green, 55-74-30-15 is given in
violet, 55-80-30-15 is given in orange and 50-75-15-9 is given in dark blue. The scenarios which apply the NLST-like nodule management are illustrated
with a circular shape. The scenarios which apply the NELSON-like nodule management are illustrated with a triangular shape. The figure does not
specify in colour or a shape the evaluated variations of the threshold values for the tumour size and growth in the NELSON-like and NLST-like
scenarios. The scenarios which resemble the eligibility criteria and nodule management protocols of the NLST and NELSON clinical trials are
illustrated in light blue. Descriptions of the scenarios are given in Table 1. Main outcomes and cost-effectiveness of the 76 baseline screening
scenarios are given in Additional file 1: Table S12
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less efficient. The efficiency frontier itself is shaped by the
applied measure of efficiency.
Our study provides two efficiency frontiers based on
weighting two major benefits of screening (LYG and
averted lung cancer deaths) against the resulting costs
(additional costs relative to the no screening scenario).
The comparative modelling study by de Koning et al. for
the USPSTF [2] in turn used “screenings per lung cancer
death averted” as a measure of the efficiency. Based on
this measure, the authors concluded that the eligibility
criteria 55-80-30-15 are more efficient than the original
NLST criteria. Considering their results for the screen-
ings per LYG as the efficiency measure, the 55-80-30-15
scenario is still more effective but less efficient than the
55-75-30-15 scenario. Although we applied the additional
cost in the numerator of the cost-effectiveness ratio, our
findings are consistent with those by de Koning et al.: the
selection criteria 55-80-30-15 are more efficient than 55-
74-30-15 if the efficiency is estimated using the cost per
averted lung cancer death ratio but less efficient based on
the cost per life year gained ratio. Overall, both efficient
frontiers outlined in our study do not include scenarios
with the 55-74-30-15 population selection criteria.
Additionally, the efficiency measure “screenings per
lung cancer death averted” used by the USPSTF to give
the recommendation for screening does not include the
harms of overdiagnosis. In our study, the cost side of
the cost-effectiveness ratio includes the costs (related
to screening and treatment) of the overdiagnosed cases
and by that the overdiagnosis is incorporated into the
measure of efficiency. In screening for lung cancer,
overdiagnosis is thought to be “the most extreme form
of length-time bias” [30]. These cases include patients
with tumours that would never have caused symptoms
or been diagnosed in clinical settings. Stopping screen-
ing at age 80 leads to substantially higher numbers of
overdiagnosed cases. This also has been shown in the
studies by ten Haaf et al. [18] and de Koning et al. [2].
In our analysis, the costs of the overdiagnosed cases ac-
count for about 30% of the difference in costs between
the 55-80-30-15 and 55-74-30-15 scenarios. If the im-
pact of overdiagnosis on the quality of life was included
into estimation of the efficiency, it would be expected
to further reduce the effectiveness and efficiency of the
screening of an older population.
Ideally, all benefits and harms which are considered to
be relevant for the identification of an optimal screening
strategy should be included into the measure of effective-
ness and efficiency. However, this would require a defined
efficiency threshold [31] or prioritisation and weighting of
the benefits and harms made by decision-makers. The aim
of our study was to evaluate strategies for an introduction
Fig. 7 The cost-effectiveness of the efficient scenarios (cost/LYG) in the sensitivity analyses. Scenario 60 is not efficient under conditions of
decreased adherence, innovative treatment and cost per CT exam of 100 euro. Scenario 65 is not efficient when cost per CT exam is 200 euro
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of a large-scale lung screening in Germany and to outline
and discuss efficient scenarios rather than provide a solid
recommendation.
Patient management strategy has a strong influence on
long-term performance and cost-effectiveness of lung
screening. The NELSON- and NLST-like nodule man-
agement protocols are comparably effective in reducing
lung cancer mortality; however, the NELSON-like strat-
egy is more successful in detection of early-stage lung
cancers, yields fewer follow-up exams, and saves costs,
and therefore may be preferable in clinical practice. The
efficient screening scenarios highlight the combinations
of the eligibility criteria and NELSON-like nodule man-
agement protocols, which may yield additional benefits
without increasing the ICER. The cut-off volume for
immediate diagnostic evaluation is a key element of the
nodule management strategy. In the NELSON trial, the
cut-off volume was defined as 500 mm3 and higher.
Our results show that a decrease to 300 mm3 would be
a more cost-effective strategy and may be justified for
clinical practice. From the health economics perspective,
our findings support previous inferences made by Horeweg
and colleagues, who assessed probabilities of cancer de-
velopment based on the NELSON data and concluded
that patients with a screen-detected nodule of volume
of 300 mm3 or more should undergo immediate diagnos-
tic work-up [20]. Additionally, variations of the nodule
management elements show that the assessment of VDT
at follow-up becomes more important if the threshold
nodule volume is less restrictive (more than 500 mm3).
It is important to note that a decreased cut-off volume
may lead to an increased number of overdiagnosed cases.
In our analysis, the majority of the overdiagnosed cases
were patients with slowly growing adenocarcinomas and
AIS. Due to their slow growth, these are rarely symptom-
atically diagnosed [32] but may be detected by screening.
Our results also suggest that scenarios which exclude the
threshold nodule volume as the indicator for immediate
diagnostic evaluation and apply the assessment of VDT (at
the follow-up exam 3 months later) as a sole malignancy
predictor can considerably reduce overdiagnosis; however,
this can come at a high price of missing LYG and averted
lung cancer deaths. Although a number of cases and the
costs of overdiagnosis can be calculated in model settings,
their effects on the health outcomes and quality of life
need to be further investigated and quantified.
In this study, the effect of screening on quality of life
could not be included in the analysis due to lack of
German data on values of quality-adjusted life years
(QALYs) across the lung cancer stages, sexes and age
groups. The cost-effectiveness ratios in terms of costs per
QALY gained would be expected to be notably higher than
the estimated cost/LYG ratios [7]. As long as the screening
shifts the major part of diagnoses towards the early-stage
cancers, more patients are likely to receive a resection op-
eration. These patients are reported to have a considerably
impaired quality of life during the first 2 years after lung
resection but it may improve later [33, 34]. Additionally,
with the application of QALYs, the negative effects of
overdiagnosis and false positives would considerably
increase [35, 36].
Several limitations are worth noting. Tumour growth
is simulated using a Gompertzian growth model which
does not capture abrupt changes in the development
(growth) of the tumour. However, other studies have
shown that cancer tumour growth can be well approxi-
mated by a Gompertz function [37]. Our approach to
modelling of false positives is rather simplified and does
not allow for a comprehensive analysis of the false-
positive outcomes at screening. The question of how to
decrease the number of false-positive cases remains
unanswered and requires additional information, which
clinical trials may provide in the future. The limitations
form a direction for further research into lung screening
in Germany. There is a need to collect detailed data on tu-
mours at time of diagnosis about their size, stage, smoking
habits of the patients, treatment costs and quality of life
of German patients with lung cancer, along with factors
affecting screening uptake among the target groups.
The cost-effectiveness of a combination of a smoking
cessation intervention with a screening program is worth
investigating.
Despite the limitations, the present study contributes
insights on the impacts of the nodule management
protocol on the effectiveness and cost-effectiveness of
the introduction of a large-scale lung screening program.
Additionally, this work is the first modelling study of
microsimulation design which examines cost-effectiveness
of the introduction of a large-scale lung screening pro-
gram in a European country. The presented findings are
comparable to the results reported in NLST [38] and pre-
vious modelling studies [2, 14, 18]. Because the developed
model contains very little input obtained from the NLST
data, comparison with the outcomes of NLST may serve
as validation of the model. Outcomes of the model for the
scenario most similar to NLST (Additional file 1: Section
2.2, Table S10) show a resembling distribution of histo-
logic classes and stages of lung cancers detected at screen-
ing and interval cancers [1]. NLST reports lung cancer
mortality outcomes relative to radiography for a median
follow-up of 6.5 years [38]. We could compare these with
the outcomes of our microsimulation model for 7 years of
follow-up (Additional file 1: Table S14). In our analysis
lung cancer mortality is considerably higher in the no
screening settings and in the NLST-resembling scenario
than reported in the trial; however, the differences be-
tween mortality rates in the screening and no screening
scenarios are close to the differences in mortality rates
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between LDCT screening and radiography observed in
NLST. Considering lung cancer mortality reduction as a
ratio, due to the higher mortality rates the model reports a
lower percentage (around 16%) in comparison to NLST
(21%) [38]. However, it still falls into the range given by
confidence interval calculations in NLST. Our model
also predicts a higher all-cause mortality rate than ob-
served in NLST. The higher mortality may be caused by
an older population and a larger proportion of current
smokers in the screened cohorts; additionally, the settings
of a clinical study and a possible “healthy-volunteer” effect
[38] may positively affect the mortality outcomes of the
clinical trial.
Overall, reduction in lung cancer mortality calculated
over a lifetime course ranges from 9.7 to 12.8% and stays
similar to the values reported in previous studies [2, 18].
Furthermore, the difference in the mortality rates be-
tween the no screening and screening arms is the basis
for the economic evaluation, and it is very similar to that
of the NLST trial. We therefore suggest that application
of survival data other than that reported in NLST has a
limited influence on the presented findings.
The cost-effectiveness has been analysed in modelling
studies in the USA [14] and Canada [18]. Due to the
application of QALYs in the study by McMahon et al.
(USA), the obtained cost-effectiveness ratios cannot be
compared. Comparing the findings to the study by the
Canadian team, the cost-effectiveness ratios obtained in
this study lie within the range given by ten Haaf et al.,
despite differences in the applied cost inputs [18].
Overall, applicability of the presented results for other
countries depends on the similarity of the cost structure
and heavy smoker prevalence between the countries.
The sensitivity analyses show that cost-effectiveness ratio
is driven by cost per CT exam and other screening-
related costs. The cost per CT exam taken in our study
is not Germany-specific and is varied in the sensitivity
analyses, giving an opportunity to transfer the results to
other countries. The costs of lung cancer treatment tend
to be higher in Germany, as in other European countries
[39]. Pharmaceutical companies continue to keep prices
higher in Germany based on the expectation that German
prices will become reference prices for the pharmaceuticals
in other European countries [40]. Lower costs of screening
and lung cancer treatment in other countries may decrease
the cost-effectiveness ratio and make population-based lung
screening more cost-effective.
Due to differences in exposure to smoking in popula-
tions, cost structures and approaches to lung cancer treat-
ment, efficient scenarios of lung screening can vary
between the European countries. However, the main find-
ings on the impacts of the nodule management protocol
and population selection criteria on the cost-effectiveness
of the screening can be applied to other countries.
Conclusions
This study quantifies the effect of nodule management
approaches on the benefits, harms and cost-effectiveness
of lung screening. Our analysis shows that the nodule
management protocol has a considerable effect on
screening performance and should be considered in
greater detail when defining optimal screening strategies.
It is the first cost-effectiveness analysis of lung cancer
screening using a microsimulation design performed in a
population-based setting in Germany. These results can
support decision-making processes in lung cancer pre-
vention and direct creation of guidelines for LDCT lung
cancer screening to benefit the German population.
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